Clinical Trial Update: Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial investigating ruxolitinib with methylprednisolone as first-line treatment for macrophage activation syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Macrophage Activation Syndrome

Drugs mentioned

• METHYLPREDNISOLONE (methylprednisolone)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Beijing Friendship Hospital | Conditions: Macrophage Activation Syndrome | Phase 3 | Status: UNKNOWN